Creatinine Clearance Cockcroft Gault Calculator
Estimate creatinine clearance for drug dosing using the Cockcroft-Gault equation. Enter values for instant results with step-by-step formulas.
Creatinine Clearance Cockcroft-Gault Calculator
Estimate creatinine clearance for drug dosing using the Cockcroft-Gault equation. Includes ideal and adjusted body weight calculations with FDA dosing categories.
Last updated: January 2026Reviewed by NovaCalculator Medical Editorial Team
Calculator
Adjust values & calculateFormula
Age in years, Weight in kg, Serum Creatinine in mg/dL. Multiply by 0.85 for female patients. The result estimates creatinine clearance in mL/min. Ideal body weight (Devine formula) should be considered for obese patients.
Last reviewed: January 2026
Worked Examples
Example 1: Standard Calculation for Male Patient
Example 2: Obese Female Patient with Adjusted Weight
Background & Theory
The Creatinine Clearance Cockcroft-Gault Calculator applies the following established principles and formulas. Clinical medicine relies on standardized measurement tools and formulas to guide diagnosis, dosing, and patient monitoring with precision and reproducibility. Pediatric and weight-sensitive drug dosing is calculated in milligrams per kilogram of body weight, a method that adjusts for physiological variation across patient sizes and ensures therapeutic drug levels without toxicity. This principle extends to adult populations for medications with narrow therapeutic indices, such as aminoglycosides and anticoagulants. Glomerular filtration rate, or GFR, is the primary index of kidney function, estimating how much blood the kidneys filter per minute. The CKD-EPI equation, developed in 2009 and refined in 2021 to remove the race variable, uses serum creatinine, age, and sex to estimate GFR, classifying chronic kidney disease stages from G1 (above 90 mL/min/1.73m²) through G5 (below 15 mL/min/1.73m²). The older Cockcroft-Gault formula remains valuable for calculating creatinine clearance to guide drug dosing. Body surface area is critical for chemotherapy dosing and certain cardiovascular assessments. The Mosteller formula, BSA = square root of (height in cm × weight in kg / 3600), is favored for its computational simplicity and clinical accuracy. Du Bois, Haycock, and Gehan-George formulas are alternatives used in specific pediatric and research settings. Fluid balance calculations track intake against output to guide intravenous therapy, particularly in critical care, surgery recovery, and burn management. The Parkland formula calculates initial fluid resuscitation for burns as 4 mL × weight in kg × percent body surface area burned, delivered over 24 hours. The Glasgow Coma Scale, scored across eye opening, verbal response, and motor response, provides a standardized neurological assessment with scores ranging from 3 (deep coma) to 15 (fully alert). The APGAR score, assessed at one and five minutes after birth across five criteria, quantifies neonatal transition to extrauterine life. Both scales support rapid clinical decision-making and interoperability across care teams.
History
The history behind the Creatinine Clearance Cockcroft-Gault Calculator traces back through the following developments. Clinical measurement as a formal discipline emerged from centuries of empirical observation systematized into reproducible tools. The measurement of body temperature became practical following Daniel Gabriel Fahrenheit's development of the mercury thermometer in 1714, which established a calibrated temperature scale. Anders Celsius introduced the centigrade scale in 1742, and Carl Wunderlich's 19th-century hospital surveys of over a million temperature readings established the normal range of 36 to 37.5 degrees Celsius, giving thermometry a clinical reference standard. Blood pressure measurement was transformed by Scipione Riva-Rocci's invention of the arm-cuff sphygmomanometer in 1896, which allowed non-invasive systolic pressure measurement. Nikolai Korotkoff's 1905 description of auscultatory sounds during cuff deflation enabled both systolic and diastolic readings, creating the method still in standard clinical use today. Willem Einthoven's invention of the electrocardiograph in 1901 and his receipt of the Nobel Prize in 1924 formalized cardiac electrical measurement and initiated a century of electrophysiological diagnostics. The first rigorous controlled clinical trial in modern medicine is credited to Austin Bradford Hill and the Medical Research Council streptomycin tuberculosis trial of 1948, which introduced randomization, control groups, and blinding as methodological cornerstones. Hill subsequently developed the criteria for causal inference in epidemiology, shaping how clinical evidence is generated and interpreted. The Glasgow Coma Scale was developed by Graham Teasdale and Bryan Jennett at the University of Glasgow in 1974 as a standardized neurological assessment for trauma patients. The APGAR score was introduced by Virginia Apgar in 1952 as a rapid neonatal assessment tool, originally developed to address inconsistency in delivery room practices. The Mosteller BSA formula was published in 1987, simplifying earlier more complex calculations for routine clinical use. The late 20th century saw the rise of clinical decision support systems embedding these formulas into hospital information technology, reducing calculation errors and improving bedside access to validated tools.
Frequently Asked Questions
Formula
CrCl (mL/min) = [(140 - Age) x Weight x (0.85 if female)] / (72 x Serum Creatinine)
Age in years, Weight in kg, Serum Creatinine in mg/dL. Multiply by 0.85 for female patients. The result estimates creatinine clearance in mL/min. Ideal body weight (Devine formula) should be considered for obese patients.
Worked Examples
Example 1: Standard Calculation for Male Patient
Problem: A 65-year-old male weighing 80 kg with a serum creatinine of 1.4 mg/dL. Calculate creatinine clearance using the Cockcroft-Gault equation.
Solution: CrCl = [(140 - 65) x 80 x 1.0] / (72 x 1.4)\nCrCl = [75 x 80] / 100.8\nCrCl = 6000 / 100.8\nCrCl = 59.5 mL/min\nFDA Category: Moderate Renal Impairment (CrCl 30-59)\nDrug doses renally cleared medications may need adjustment.
Result: CrCl: 59.5 mL/min (Moderate Impairment) - Check drug-specific dosing recommendations
Example 2: Obese Female Patient with Adjusted Weight
Problem: A 50-year-old female, height 165 cm, actual weight 110 kg, serum creatinine 0.9 mg/dL. Calculate CrCl using actual weight, ideal body weight, and adjusted body weight.
Solution: Height in inches: 165 / 2.54 = 64.96 in\nIBW = 45.5 + 2.3 x (64.96 - 60) = 45.5 + 11.4 = 56.9 kg\nABW = 56.9 + 0.4 x (110 - 56.9) = 56.9 + 21.2 = 78.1 kg\nActual weight: 110 kg > 1.2 x 56.9 (68.3 kg) = Obese\n\nCrCl (actual wt): [(140-50) x 110 x 0.85] / (72 x 0.9) = 130.0 mL/min\nCrCl (IBW): [(140-50) x 56.9 x 0.85] / (72 x 0.9) = 67.3 mL/min\nCrCl (ABW): [(140-50) x 78.1 x 0.85] / (72 x 0.9) = 92.3 mL/min
Result: CrCl: 92.3 mL/min (using ABW) vs 130.0 (actual) vs 67.3 (IBW) - Use ABW for obese patients
Frequently Asked Questions
What is the Cockcroft-Gault equation and why is it still used?
The Cockcroft-Gault equation was published by Donald Cockcroft and Henry Gault in 1976 as a method to estimate creatinine clearance (CrCl) from serum creatinine, age, weight, and sex. Despite being nearly five decades old, it remains one of the most widely used renal function estimators in clinical practice, particularly for drug dosing purposes. The majority of drug manufacturers conducted pharmacokinetic studies using Cockcroft-Gault to establish renal dosing recommendations in FDA-approved drug labels. This historical dependence means that using alternative equations like CKD-EPI for drug dosing may not accurately match the populations studied during drug development, potentially leading to incorrect dose adjustments.
How does the Cockcroft-Gault equation differ from the CKD-EPI equation?
The Cockcroft-Gault equation estimates creatinine clearance (CrCl), while the CKD-EPI equation estimates glomerular filtration rate (eGFR). Though related, these are different measurements. Creatinine clearance slightly overestimates true GFR because creatinine is both filtered by glomeruli and secreted by renal tubules. The Cockcroft-Gault equation incorporates actual body weight, while CKD-EPI normalizes to body surface area. CKD-EPI is recommended for CKD staging and diagnosis, while Cockcroft-Gault is preferred for drug dosing because most pharmaceutical dosing studies used it. The CKD-EPI equation was developed using more modern creatinine assays and a larger, more diverse study population.
When should ideal body weight versus actual body weight be used in the Cockcroft-Gault equation?
The original Cockcroft-Gault equation was developed using actual body weight, but this can significantly overestimate creatinine clearance in obese patients because excess adipose tissue does not proportionally increase creatinine production. For patients whose actual body weight exceeds their ideal body weight by more than 20 percent, many pharmacists and clinicians use adjusted body weight (ABW), calculated as ideal body weight plus 40 percent of the difference between actual and ideal weight. Some drug dosing references specify which weight to use. For underweight patients, actual body weight should generally be used. The choice of weight measure can result in clinically meaningful differences in calculated CrCl, potentially affecting drug dosing decisions.
What are the limitations of using serum creatinine to estimate kidney function?
Serum creatinine has several important limitations as a marker of kidney function. Creatinine production depends on muscle mass, so patients with reduced muscle mass (elderly, malnourished, amputees, cirrhotic) may have falsely low serum creatinine levels that overestimate their true kidney function. Conversely, very muscular individuals may have elevated serum creatinine without actual kidney impairment. Creatinine levels do not rise above the normal range until approximately 50 percent of kidney function is lost, creating a diagnostic blind spot for early kidney disease. Certain medications (trimethoprim, cimetidine) inhibit tubular secretion of creatinine, raising serum levels without affecting true GFR. Diet can also affect creatinine levels, particularly high meat intake.
How do FDA drug dosing categories correspond to Cockcroft-Gault creatinine clearance values?
The FDA established standardized renal function categories for drug dosing based on Cockcroft-Gault estimated creatinine clearance. Normal renal function is defined as CrCl of 90 mL/min or higher. Mild renal impairment corresponds to CrCl of 60 to 89 mL/min. Moderate renal impairment is CrCl 30 to 59 mL/min. Severe renal impairment is CrCl 15 to 29 mL/min. End-stage renal disease is CrCl below 15 mL/min or requiring dialysis. These categories are used in drug package inserts to provide dosing recommendations. Clinicians should check the specific drug labeling, as some medications use different cutoffs or different renal function equations for their dosing recommendations.
How does age affect the Cockcroft-Gault calculation and its clinical implications?
Age is a critical variable in the Cockcroft-Gault equation, appearing in the numerator as (140 minus age). This reflects the well-established physiological decline in kidney function with aging, estimated at approximately 1 mL/min per year of GFR decline after age 30 to 40. The equation predicts that creatinine clearance decreases linearly with age, independent of other factors. However, this age-related decline occurs simultaneously with age-related loss of muscle mass, which reduces creatinine production and can mask the decline in serum creatinine levels. This means that an elderly patient with a normal serum creatinine may still have significantly impaired kidney function. The Cockcroft-Gault equation accounts for this phenomenon better than relying on serum creatinine alone.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy